RVMD vs. WAT: Revolution Medicines vs. Waters Stock Comparison

Company Profile

Revolution Medicines (RVMD) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RVMD is classified in Biotechnology while WAT is classified in Life Sciences Tools & Services.

Waters (WAT) has more than two decades of public-market history since November 17, 1995, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Waters (WAT) reports 1.12%, ranking against industry peers normally.

Both Revolution Medicines (RVMD) at 0.00% and Waters (WAT) at 1.76% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Waters (WAT) reports 11.38%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Waters (WAT) reports revenue growth of 6.99%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: Waters (WAT) reports EPS growth of 0.47%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Revolution Medicines (RVMD) shows current ratio of 8.36 against its industry benchmark, while Waters (WAT) has no reading this period.

Both Revolution Medicines (RVMD) at 0.50 and Waters (WAT) at 0.34 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Revolution Medicines (RVMD) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Revolution Medicines (RVMD) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Waters (WAT) trades at 191.46 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

Waters (WAT) at 8.01 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

Waters (WAT) at 2.94 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

Valuation Metrics